For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
78
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      335
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose of Review

          This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).

          Recent Findings

          Over the course of the last 5–6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients.

          Summary

          Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          Genomic Classification and Prognosis in Acute Myeloid Leukemia

          Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger … (2016)
          New England Journal of Medicine, 374(23), 2209-2221
          Article 0 comments Cited 1033 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

            Courtney D DiNardo, Brian Jonas, Vinod Pullarkat … (2020)
            Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
            Article 0 comments Cited 745 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

              Richard M Stone, Sumithra J Mandrekar, Ben L Sanford … (2017)
              Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population.
              Article 0 comments Cited 503 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Michael Wysota: mwysota@montefiore.org
                Marina Konopleva: marina.konopleva@einsteinmed.edu
                Journal
                Journal ID (nlm-ta): Curr Oncol Rep
                Journal ID (iso-abbrev): Curr Oncol Rep
                Title: Current Oncology Reports
                Publisher: Springer US (New York )
                ISSN (Print): 1523-3790
                ISSN (Electronic): 1534-6269
                Publication date (Electronic): 19 March 2024
                Publication date PMC-release: 19 March 2024
                Publication date (Print): 2024
                Volume: 26
                Issue: 4
                Pages: 409-420
                Affiliations
                [1 ]Department of Oncology, Montefiore Medical Center, ( https://ror.org/044ntvm43) 111 East 210 Street, Bronx, NY 10467 USA
                [2 ]Montefiore Medical Center/Albert Einstein College of Medicine, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, Ullmann Building, ( https://ror.org/05cf8a891) 1300 Morris Park AvenueRoom 915, Bronx, NY 10461 USA
                [3 ]Albert Einstein College of Medicine, ( https://ror.org/05cf8a891) Bronx, NY USA
                Article
                Publisher ID: 1503
                DOI: 10.1007/s11912-024-01503-y
                PMC ID: 11021231
                PubMed ID: 38502417
                SO-VID: fc608f41-a395-490d-abc8-27973b3f442a
                Copyright © © The Author(s) 2024
                License:

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                Date accepted : 1 February 2024
                Categories
                Subject: Review
                Custom metadata
                issue-copyright-statement © Springer Science+Business Media, LLC, part of Springer Nature 2024

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: acute myeloid leukemia,novel therapeutics,molecular targets,aml,immune therapy
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: acute myeloid leukemia, novel therapeutics, molecular targets, aml, immune therapy

                Comments

                Comment on this article